The serum level of leucine-rich alpha-2 glycoprotein to differentiate between ischemic and non-ischemic retinal vein occlusion

• VEGF is the main factor to RVO, however other cytokines may be correlated with this disease. LRG1 is involved in proliferative diabetic retinopathy(PDR) and age-related macular degeneration (AMD) • Our study shows serum LRG1 is elevated in RVO compared to control, particulary in ischemic RVO.Consequently, LRG1 may served as a potential biomarker and/or therapeutic target for ischemic RVO in the future • The elevation of serum LRG1 may be related to the progression of RVO, and long-term follow-up should be conducted for RVO patients at different stages To assess the levels of leucine-rich α-2 glycoprotein-1 (LRG1) in aqueous humour and serum of patients with retinal vein occlusion (RVO) and to investigate the correlation between LRG1 and RVO. This is a cross-sectional study. This study involved 41 patients with retinal vein occlusion (RVO), comprising 15 individuals with central retinal vein occlusion (CRVO), 26 with branch retinal vein occlusion (BRVO), and 36 with cataracts. The study cohort was further categorized into ischemia (n=15) and non-ischemic subtypes (n=26). Aqueous humor (100μL) was obtained after intravitreal anti-VEGF injection or cataract surgery. LRG1 was quantified using ELISA kits. The aqueous and serum concentrations of LRG1 were considerably elevated in the eyes of individuals with RVO compared to controls (All P